Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2003 by Facet Biotech.
Recruitment status was:  Active, not recruiting
Facet Biotech
Information provided by:
Facet Biotech Identifier:
First received: March 15, 2002
Last updated: June 23, 2005
Last verified: October 2003
The purpose of this phase II study is to evaluate an investigational monoclonal antibody for the treatment of glucocorticoid-refractory Graft Versus Host Disease (GVHD). Patients diagnosed with GVHD who have not responded satisfactorily to, or are intolerant of, treatment with standard agents will be considered for entry. Patients will be allowed to continue on their other immunosuppressive drugs at stable doses during the trial. The research is being conducted at up to 20 clinical research sites in the US.

Condition Intervention Phase
Graft-vs-Host Disease
Drug: Visilizumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter Clinical Trial Evaluating the Use of Humanized Monoclonal Anti-CD3 Antibody Visilizumab(Nuvion) as Second-line Therapy for Glucocorticoid-Refractory, Acute Graft-Versus-Host Disease

Resource links provided by NLM:

Further study details as provided by Facet Biotech:

Estimated Enrollment: 80
Study Start Date: March 2002

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Grade II to IV GVHD
  • Clinical findings: skin thickening, joint contraction, oral ulceration, diarrhea.
  • History of allogeneic hematopoietic cell transplant (HCT).
  • Patients must have failed to respond or clearly progress to previous therapy on or before day +100 posttransplant.
  • Patients must have adequate renal, hepatic, cardiac function and hematologic values
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00032279

United States, California
City of Hope National Medical Center
Duarte, California, United States, 91910
Stanford University Medical Center
Stanford, California, United States, 94305-5623
United States, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612
United States, Indiana
University Hospital
Indianapolis, Indiana, United States, 46202
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
University of Massachusetts Medical School
Worcester, Massachusetts, United States, 01605
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, New York
The New York Hospital Cornell Medical Center
New York, New York, United States, 10021
Westchester Medical Center
Valhalla, New York, United States, 10595
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27705
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Ohio State University
Columbus, Ohio, United States, 43210
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232-6310
United States, Texas
Baylor University Medical Center
Dallas, Texas, United States, 75246
Baylor College of Medicine
Houston, Texas, United States, 77030
MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
Facet Biotech
  More Information Identifier: NCT00032279     History of Changes
Obsolete Identifiers: NCT00042744
Other Study ID Numbers: 1589
Study First Received: March 15, 2002
Last Updated: June 23, 2005

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on April 28, 2017